stella
beta
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC — Stella
Recruiting
Back to Non-Small Cell Lung Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Johns Hopkins University, Baltimore, Maryland
View full record on ClinicalTrials.gov